Trial Profile
Efficacy and safety of glecaprevir/pibrentasvir combination tablets for patients infected with pan-genotypic hepatitis C virus
Status:
Active, no longer recruiting
Phase of Trial:
Phase IV
Latest Information Update: 29 Jul 2021
Price :
$35
*
At a glance
- Drugs Glecaprevir/pibrentasvir (Primary)
- Indications Hepatitis C
- Focus Therapeutic Use
- 22 May 2020 Status changed from recruiting to active, no longer recruiting.
- 02 Jan 2018 Status changed from not yet recruiting to recruiting.
- 02 Nov 2017 New trial record